Marc-Andrea Baertsch1, Katharina Kriegsmann1, Petra Pavel2, Thomas Bruckner3, Michael Hundemer1, Mark Kriegsmann4, Anthony D Ho1, Hartmut Goldschmidt1,5, Patrick Wuchter6. 1. Department of Medicine V (Hematology, Oncology and Rheumatology), University Hospital Heidelberg, Heidelberg, Germany. 2. Stem Cell Laboratory, IKTZ Heidelberg GmbH, Heidelberg, Germany. 3. Institute of Medical Biometry und Informatics, Heidelberg University, Heidelberg, Germany. 4. Institute of Pathology, Heidelberg University, Heidelberg, Germany. 5. National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. 6. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hesse, Mannheim, Germany.
Abstract
BACKGROUND: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. METHODS: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). RESULTS: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004). CONCLUSION: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor.
BACKGROUND: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. METHODS: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). RESULTS: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004). CONCLUSION: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor.
Authors: A I Chen; T Bains; S Murray; R Knight; K Shoop; J Bubalo; C Fowler; S Slater; R T Maziarz Journal: Bone Marrow Transplant Date: 2012-05-07 Impact factor: 5.483
Authors: Miguel-Angel Perales; Izaskun Ceberio; Philippe Armand; Linda J Burns; Robert Chen; Peter D Cole; Andrew M Evens; Ginna G Laport; Craig H Moskowitz; Uday Popat; Nishitha M Reddy; Thomas C Shea; Julie M Vose; Jeffrey Schriber; Bipin N Savani; Paul A Carpenter Journal: Biol Blood Marrow Transplant Date: 2015-03-12 Impact factor: 5.742
Authors: H Tilly; U Vitolo; J Walewski; M Gomes da Silva; O Shpilberg; M André; M Pfreundschuh; M Dreyling Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Katharina Lisenko; Petra Pavel; Thomas Bruckner; Joe Puthenparambil; Michael Hundemer; Anita Schmitt; Mathias Witzens-Harig; Anthony D Ho; Patrick Wuchter Journal: J Clin Apher Date: 2016-04-20 Impact factor: 2.821
Authors: M Pozotrigo; N Adel; H Landau; A Lesokhin; N Lendvai; D J Chung; D Chimento; E Riedel; X Chen; L Reich; R Comenzo; S Giralt; H Hassoun Journal: Bone Marrow Transplant Date: 2013-01-21 Impact factor: 5.483
Authors: Ahmad S Alsaeed; Mona J Najib; Sameer M Al Amoudi; Ihab Y Elhemaidi; Ahmed A Absi; Majed D Al Ahmadi; Saleem K Eldadah; Walaa A Rajkhan; Manar M Khalil; Mohammed H Almohammadi Journal: Saudi Med J Date: 2022-06 Impact factor: 1.422